1-2 of 2
David E. Weng
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma

Free
Ravi K. Amaravadi, Russell J. Schilder, Lainie P. Martin, Myron Levin, Martin A. Graham, David E. Weng, Alex A. Adjei
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (11): 2569–2575.
https://doi.org/10.1158/1535-7163.MCT-15-0475
Published: 03 November 2015
View article titled, A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma
Open the PDF for A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma in another window
Includes: Supplementary data
Journal Articles

A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors

Free
David E. Weng, Paul A. Masci, Susan F. Radka, T. Elise Jackson, Patricia A. Weiss, Ram Ganapathi, Paul J. Elson, William B. Capra, Vann P. Parker, Jennifer A. Lockridge, J. Wayne Cowens, Nassim Usman, Ernest C. Borden
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2005) 4 (6): 948–955.
https://doi.org/10.1158/1535-7163.MCT-04-0210
Published: 14 June 2005
View article titled, A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors
Open the PDF for A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors in another window